Valneva to Participate at U.S. and European Investor Conferences in June
Key topics for discussion include Valneva's commercial stage vaccines and its differentiated portfolio of vaccine candidates, including VLA15, the world's leading Lyme disease vaccine candidate. VLA15 is partnered with Pfizer and currently being evaluated in a pivotal Phase 3 trial for which the Company expects first data at the end of 2025.
Institutional investors who would like to meet 1on1 with management at any of the below conferences are asked to submit a request to their representative at the respective bank.
Jefferies Global Healthcare Conference
Format Fireside chat and investor meetingsDate/ time June 5, 2025, 11:40am ETWebcast Link. A replay of the webcast will also be available in the 'Investor' section of the Valneva website.Location New York
Goldman Sachs 46th Annual Global Healthcare Conference:
Format Fireside chat and investor meetingsDate/ time June 9, 2025, 1:20pm ET Location Miami, FL
Oddo BHF Nextcap Forum:
Format Investor meetings onlyDate/ time June 12, 2025Location Virtual
BNP Paribas SMID Cap Conference:
Format Investor meetings onlyDate/ time June 18, 2025Location Paris, France
About Valneva SE
We are a specialty vaccine company that develops, manufactures, and commercializes prophylactic vaccines for infectious diseases addressing unmet medical needs. We take a highly specialized and targeted approach, applying our deep expertise across multiple vaccine modalities, focused on providing either first-, best- or only-in-class vaccine solutions.
We have a strong track record, having advanced multiple vaccines from early R&D to approvals, and currently market three proprietary travel vaccines.Revenues from our growing commercial business help fuel the continued advancement of our vaccine pipeline. This includes the only Lyme disease vaccine candidate in advanced clinical development, which is partnered with Pfizer, the world's most clinically advanced Shigella vaccine candidate, as well as vaccine candidates against the Zika virus and other global public health threats. More information is available at www.valneva.com.
Valneva Investor and Media ContactsLaetitia Bachelot-FontaineVP, Global Communications and European Investor RelationsM +33 (0)6 4516 7099Laetitia.bachelotfontaine@valneva.com
Joshua Drumm, Ph.D.VP, Global Investor Relations M +001 917 815 4520joshua.drumm@valneva.com
Forward-Looking StatementsThis press release contains certain forward-looking statements relating to the business of Valneva, including with respect to use and regulatory review of existing products. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be sustained in the future. In some cases, you can identify forward-looking statements by words such as 'could,' 'should,' 'may,' 'expects,' 'anticipates,' 'believes,' 'intends,' 'estimates,' 'aims,' 'targets,' or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties and delays involved in the development and manufacture of vaccines, unexpected clinical trial results or new adverse events, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Valneva is providing this information as of the date of this press release and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.
Attachment
2025_05_26_VLA_June_2025_Conferences_PR_EN_Final
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Jim Cramer Says Affirm is Going to $100
Affirm Holdings, Inc. (NASDAQ:AFRM) is one of the stocks Jim Cramer recently discussed. When a viewer called looking for confirmation of Cramer's bullish view on the company, he remarked: 'It's at $72, it's going to $100, okay? Now, I usually don't talk like that except for, I talk like that with Palantir. 72 goes to 100. I say get on board, Affirm. Yes, get on board. Affirm.' Photo by Yiorgos Ntrahas on Unsplash Affirm Holdings, Inc. (NASDAQ:AFRM) provides a payment platform offering point-of-sale financing, merchant commerce solutions, and a consumer app that enables purchases to be paid over time. Cramer commented on the stock in an April episode. He remarked: 'Well, I think the world of Affirm, but it's what I call an earnings stock. In other words, it doesn't really do anything, change direction until you add the earnings. Right now, the direction is down. When we see the company report on May 8th, I think that therefore we could change direction again because I think that there's no doubt Matt Levchin delivers good quarter after good quarter. But then in between, it trades down and you're dealing with that. I don't think it reverses until we get to May 8th.' Since the above comment, the company's stock price has gained over 100%. While we acknowledge the potential of AFRM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Insider
an hour ago
- Business Insider
B.Riley Financial Remains a Buy on TeraWulf Inc (WULF)
Financial analyst Lucas Pipes maintained a Buy rating on TeraWulf Inc yesterday and set a price target of $14.00. The company's shares closed yesterday at $8.97. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Pipes is a 5-star analyst with an average return of 25.5% and a 51.94% success rate. In addition to Financial, TeraWulf Inc also received a Buy from Citizens JMP's Gregory P Miller in a report issued yesterday. However, on the same day, KBW maintained a Hold rating on TeraWulf Inc (NASDAQ: WULF). WULF market cap is currently $3.41B and has a P/E ratio of -25.33. Based on the recent corporate insider activity of 69 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of WULF in relation to earlier this year. Most recently, in June 2025, Catherine J. Motz, a Director at WULF sold 21,182.00 shares for a total of $83,033.44.
Business Insider
an hour ago
- Business Insider
Applied Materials (AMAT) Receives a Hold from CFRA
CFRA analyst Brooks Idlet maintained a Hold rating on Applied Materials yesterday and set a price target of $167.00. The company's shares closed yesterday at $161.76. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Idlet is an analyst with an average return of -8.4% and a 60.00% success rate. In addition to CFRA, Applied Materials also received a Hold from Barclays's Thomas O'Malley in a report issued yesterday. However, on the same day, Bernstein maintained a Buy rating on Applied Materials (NASDAQ: AMAT). Based on Applied Materials' latest earnings release for the quarter ending April 27, the company reported a quarterly revenue of $7.1 billion and a net profit of $2.14 billion. In comparison, last year the company earned a revenue of $6.65 billion and had a net profit of $1.72 billion Based on the recent corporate insider activity of 39 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AMAT in relation to earlier this year. Most recently, in June 2025, Adam Sanders, the Corp. Controller & CAO of AMAT sold 562.00 shares for a total of $100,373.20.
